生物技术公司Arvinas Holding Company LLC(股票代码:ARVN)今日遭遇重挫,盘中一度大跌5.89%。从相关新闻资料看,该公司在2024年10月31日早盘出现股价剧烈波动,最高下跌5.5%,报26.14美元。
此前公布的最新财报显示,Arvinas Holding营业收入为7650万美元,但净利润为-3520万美元,每股亏损0.49美元。亏损状况可能是导致投资者对该公司前景信心受挫、引发抛售的一大原因。
不过,该公司在药物研发管线上还是取得了一些进展,据介绍其旗下的3个主要产品线bavdegalutamide、ARV-471和ARV-766正在临床试验阶段。但也有分析人士指出,短期内这些产品难以为公司带来实质性收益,或也是导致投资者失去耐心的一个因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.